ImmunityBio, Inc.
IBRX
株式のランク
#2197
ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and... ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell) immune system. ImmunityBio currently has several therapeutic candidates in advanced clinical development, with agents undergoing Phase II or III trials. These investigational treatments are aimed at various liquid and solid tumors, such as bladder, pancreatic, and lung cancers, as well as significant infectious pathogens including SARS-CoV-2 and HIV. The company actively engages in strategic partnerships, holding collaboration agreements with esteemed organizations like the National Cancer Institute, the National Institute of Deafness and Communication Disorders, and Amyris, Inc. Additionally, ImmunityBio has secured licensing agreements with numerous entities, including CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc.
株価
$8.77
最終同期: 2026-10-20
時価総額
$9.29B
変化（1日）
4.12%
変化（1年）
259.29%
国
US
取引 ImmunityBio, Inc. (IBRX)
カテゴリー
Healthcare
ImmunityBio, Inc.（IBRX）の収益
Jun 2026 時点の収益 TTM: $165.79M
ImmunityBio, Inc. の最新の財務報告によると、現在の収益 (TTM) は $165.79M です。2023 年には $622.00K の収益があり、これは 2022 年の $240.00K と比較して 増加 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
ImmunityBio, Inc. の収益履歴（2013 ～ 2026）
各年末の収益
| 年 | 収益 | 変化 |
|---|---|---|
| 2026 (TTM) | $165.79M | 1,024.39% |
| 2024 | $14.75M | 2,270.58% |
| 2023 | $622.00K | 159.17% |
| 2022 | $240.00K | -74.30% |
| 2021 | $934.00K | 54.38% |
| 2020 | $605.00K | 1,306.98% |
| 2019 | $43.00K | -8.51% |
| 2018 | $47.00K | 4.44% |
| 2017 | $45.00K | 2.27% |
| 2016 | $44.00K | -81.36% |
| 2015 | $236.00K | -63.18% |
| 2014 | $641.00K | 6.83% |
| 2013 | $600.00K | 0.00% |
同業他社の収益
| 企業 | 収益 | 収益の差 | 国 |
|---|---|---|---|
| $12.62B | 7,514.54% |
US
|
|
| $2.23B | 1,243.85% |
US
|
|
| $15.74B | 9,396.43% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 3,531.83% |
NL
|
